+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
1 Aug 2016

In clinical trial what is the meaning of MASKING (or Blinding)?

/
Posted By
/
Comments0
/
A clinical trial design strategy in which one or more parties involved in the trial, such as the investigator or participants, do not know which participants have been assigned which interventions.
Blinding or masking (the process of keeping the study group assignment hidden after allocation) is commonly used to reduce the risk of bias in clinical trials with two or more study groups.
Types of Masking include Open Label, Single Blind Masking, and Double Blind Masking.
OPEN LABEL
Describes a clinical trial in which masking is not used. This means that all parties involved in the trial know which participants have been assigned which interventions.

SINGLE BLIND MASKING
A type of Masking in which one party involved in the clinical trial, either the investigator or participants, does not know which participants have been assigned which interventions.

DOUBLE BLIND MASKING
A type of Masking in which two or more parties involved in the clinical trial do not know which participants have been assigned which interventions. Typically, the parties include the investigator and participants.

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.